Cargando…
S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642318/ http://dx.doi.org/10.1097/01.HS9.0000843840.23851.76 |
| _version_ | 1784826280935424000 |
|---|---|
| author | Meyer, E. Pavlova, A. Gandhi, A. Hoeg, R. Oliai, C. Mehta, R. Srour, S. McGuirk, J. Waller, E. Fernhoff, N. Killian, M. S. Mcclellan, J. Putnam, A. Shaw, B. Abedi, M. Negrin, R. |
| author_facet | Meyer, E. Pavlova, A. Gandhi, A. Hoeg, R. Oliai, C. Mehta, R. Srour, S. McGuirk, J. Waller, E. Fernhoff, N. Killian, M. S. Mcclellan, J. Putnam, A. Shaw, B. Abedi, M. Negrin, R. |
| author_sort | Meyer, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9642318 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96423182022-11-14 S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES Meyer, E. Pavlova, A. Gandhi, A. Hoeg, R. Oliai, C. Mehta, R. Srour, S. McGuirk, J. Waller, E. Fernhoff, N. Killian, M. S. Mcclellan, J. Putnam, A. Shaw, B. Abedi, M. Negrin, R. Hemasphere Oral Sessions Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9642318/ http://dx.doi.org/10.1097/01.HS9.0000843840.23851.76 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Meyer, E. Pavlova, A. Gandhi, A. Hoeg, R. Oliai, C. Mehta, R. Srour, S. McGuirk, J. Waller, E. Fernhoff, N. Killian, M. S. Mcclellan, J. Putnam, A. Shaw, B. Abedi, M. Negrin, R. S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES |
| title | S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES |
| title_full | S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES |
| title_fullStr | S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES |
| title_full_unstemmed | S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES |
| title_short | S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES |
| title_sort | s237: orca-t, an engineered allograft, results in high gvhd-free and relapse-free survival following myeloablative conditioning for hematological malignancies |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642318/ http://dx.doi.org/10.1097/01.HS9.0000843840.23851.76 |
| work_keys_str_mv | AT meyere s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT pavlovaa s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT gandhia s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT hoegr s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT oliaic s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT mehtar s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT srours s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT mcguirkj s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT wallere s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT fernhoffn s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT killianms s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT mcclellanj s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT putnama s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT shawb s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT abedim s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies AT negrinr s237orcatanengineeredallograftresultsinhighgvhdfreeandrelapsefreesurvivalfollowingmyeloablativeconditioningforhematologicalmalignancies |